December 12, 2023

Medicaroid Corporation

Regulatory Approval Application Filed for the Use of the hinotori™ Surgical Robot System in Respiratory Surgery

Medicaroid Corporation (HQ: Kobe, Japan; Board Director, CEO and President Koji Muneto, hereinafter referred to as "Medicaroid") announced that an application for regulatory approval was filed with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan on November 30, 2023, for the use of the hinotori Surgical Robot System (hereinafter referred to as “the hinotori”) in respiratory surgery.

The hinotori is the first made-in-Japan robotic-assisted surgery system which received a Japanese regulatory approval for the use in urology in August 2020. At the time of the first approval, the application was limited to urology. The indication was expanded to gastroenterology and gynecology in October 2022 and now the hinotori is clinically used in several medical institutions in Japan. In September 2023, a regulatory approval was received in Singapore, which was the first overseas approval for the hinotori.

This application is for the use of the hinotori in respiratory surgery to add to the three existing indications.

Through its medical robots, Medicaroid will continue to support an abundant society where all patients, patients’ family, and healthcare workers can live with peace of mind.

hinotori™ Surgical Robot System

JMDN:	Surgical robot unit
Sales name:	hinotori™ Surgical Robot System
Manufacturer:	Medicaroid Corporation



Operation Unit　　Surgeon Cockpit

Product Appearance

Contact: Corporate Planning Department
Medicaroid Corporation
Tel: 078-303-8769